Amylyx Pharmaceuticals (AMLX) Restructuring Costs (2024)
Amylyx Pharmaceuticals (AMLX) posted quarterly Restructuring Costs of $22.9 million for Q2 2024.
Amylyx Pharmaceuticals (AMLX) Restructuring Costs (2024) Analysis & Trends
Amylyx Pharmaceuticals' Restructuring Costs history runs 1 years deep, the most recent figure standing at $22.9 million for Q2 2024.
- In Q2 2024, Restructuring Costs changed N/A year-over-year to $22.9 million; the TTM figure through Jun 2025 stood at $22.9 million (changed N/A YoY), while the FY2024 annual figure was $22.9 million, changed N/A from the prior year.
- Restructuring Costs for Q2 2024 stood at $22.9 million.
- The five-year high for Restructuring Costs was $22.9 million in Q2 2024, with the low at $22.9 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 86.50 Bn | 85.53 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.71 Bn | 39.05 Bn | 2.15 Bn |
| 3 | Zoetis | 30.86 Bn | 29.18 Bn | 1.80 Bn |
| 4 | Takeda Pharmaceutical | 28.50 Bn | 22.70 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.06 Bn | 19.40 Bn | 683.80 Mn |
| 6 | Viatris | 18.84 Bn | 17.95 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn |
| 8 | Vireo Growth | 11.86 Bn | 11.71 Bn | 59.30 Mn |
| 9 | Elanco Animal Health | 11.77 Bn | 11.24 Bn | 798.00 Mn |
| 10 | Amylyx Pharmaceuticals | 3.91 Bn | 3.91 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 22.85 Mn |